Post by RLC on Jun 3, 2015 13:53:48 GMT
www.streetinsider.com/Press+Releases/OncoSec+Medical+Announces+$13.6+Million+Registered+Direct+Offering/10621233.html
SAN DIEGO, June 3, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share.
The gross proceeds of the offering are approximately $13.6 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $12.6 million. OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Life Science Partners acted as financial advisors to OncoSec in connection with the transaction. The offering is expected to close on June 5, 2015, subject to customary closing conditions.
SAN DIEGO, June 3, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share.
The gross proceeds of the offering are approximately $13.6 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $12.6 million. OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Life Science Partners acted as financial advisors to OncoSec in connection with the transaction. The offering is expected to close on June 5, 2015, subject to customary closing conditions.
